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Abstract
Background: Chronic Chagas disease presents different clinical manifestations ranging from asymptomatic (namely
indeterminate) to severe cardiac and/or digestive. Previous results have shown that the immune response plays an
important role, although no all mechanisms are understood. Immunoregulatory mechanisms such as apoptosis are
important for the control of Chagas disease, possibly affecting the morbidity in chronic clinical forms. Apoptosis has
been suggested to be an important mechanism of cellular response during T. cruzi infection. We aimed to further
understand the putative role of apoptosis in Chagas disease and its relation to the clinical forms of the disease.
Methods: Apoptosis of lymphocytes, under antigenic stimuli (soluble T. cruzi antigens – TcAg) where compared to
that of non-stimulated cells. Apoptosis was evaluated using the expression of annexin and caspase 3+ by T cells
and the percentage of cells positive evaluated by flow cytometry. In addition activation and T cell markers were
used for the identification of TCD4+ and TCD8+ subpopulations. The presence of intracellular and plasma cytokines
were also evaluated. Analysis of the activation status of the peripheral blood cells showed that patients with Chagas
disease presented higher levels of activation determined by the expression of activation markers, after TcAg
stimulation. PCR array were used to evaluate the contribution of this mechanism in specific cell populations from
patients with different clinical forms of human Chagas disease.
Results: Our results showed a reduced proliferative response associated a high expression of T CD4+CD62L− cells in
CARD patients when compared with IND group and NI individuals. We also observed that both groups of patients
presented a significant increase of CD4+ and CD8+ T cell subsets in undergoing apoptosis after in vitro stimulation
with T. cruzi antigens. In CARD patients, both CD4+ and CD8+ T cells expressing TNF-α were highly susceptible to
undergo apoptosis after in vitro stimulation. Interestingly, the in vitro TcAg stimulation increased considerably the
expression of cell death TNF/TNFR superfamily and Caspase family receptors genes in CARD patients.
Conclusions: Taken together, our results suggest that apoptosis may be an important mechanism for the control
of morbidity in T. cruzi infection by modulating the expression of apoptosis genes, the cytokine environment and/
or killing of effector cells.
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Background
Chagas disease, a neglected disease caused by Trypanosoma
cruzi, remains a serious public health problem and affects
about 10 million people in Latin America [1]. Chronic car-
diomyopathy represents the most important and severe
manifestation of human Chagas disease, eventually affecting
approximately 20–30 % of individuals. The majority of the
chronically affected individuals present the indeterminate
(IND) form of the disease, with an apparent absence of
morbidity [2, 3]. Epidemiological studies in endemic areas
have shown that 2–5 % of patients will evolve each year
from the indeterminate to the cardiac clinical form of the
disease [4].
Although the pathophysiology of Chagas disease is not
completely understood, it is widely accepted that the in-
volvement of the immune response is critical in deter-
mining the disease outcome [5–8]. While the balance
between inflammatory and anti-inflammatory cytokines
produced by circulating cells in patients with IND form
leans towards to an anti-inflammatory profile, patients
with chagasic cardiomyopathy seem to display a predom-
inantly inflammatory pattern [6, 9, 10]. The type of im-
mune response induced in these individuals seems to be
critical for the maintenance of a “healthy” balance between
the parasite and the host [11]. In fact, several studies have
demonstrated that immunoregulatory mechanisms are
important for the control of infection, possibly affecting
disease morbidity in chronic clinical forms [11, 12] such
as T-cell suppression, polyclonal lymphocyte activation,
and regulatory cytokines [13, 14]. Infection with T. cruzi
leads to polyclonal lymphocyte activation [15], which, by
itself, promotes T-cell apoptosis [16, 17]. In addition,
antigens released by T. cruzi, such as trans-sialidase
and HSP70, induce lymphocyte apoptosis [18, 19]. There-
fore, it is possible that the parasite exploits host cell apop-
tosis to evade the immune response. Evidences also
indicate that apoptosis plays a role in the resolution of
inflammation [20].
In the present work, we evaluated the contribution of
apoptosis in specific T cell populations on the develop-
ment/maintenance of different clinical manifestations of
human Chagas disease. Our findings demonstrated that in
vitro stimulation with T. cruzi antigens induce lymphocyte
apoptosis by continued cell activation, modulation of the
expression of apoptosis genes and cytokine secretion pro-
file. These findings may contribute to the regulation of im-
mune response during human Chagas disease.
Methods
Study population
The patients that agreed to participate in this study were
identified and selected from those being attended at the
Referral Outpatient Center for Chagas Disease, which is
located at the Clinics Hospital of the Federal University
of Minas Gerais (UFMG), Brazil, under the medical care
of one of us (MOCR). These patients were enrolled in a
prospective cohort study initiated 20 years ago as previ-
ously described [13]. Patients infected with T. cruzi were
grouped as indeterminate (IND) or with cardiomyopathy
(CARD). The IND group included 15 asymptomatic in-
dividuals with age ranging from 24 to 66 years (mean of
39.6 ± 10.3), with no significant alterations in electrocar-
diography, chest X-ray and echocardiogram. The CARD
group included 15 patients with age ranging from 23 to
69 years (mean of 48 ± 12.52) presenting dilated cardio-
myopathy, characterized by the echocardiographic find-
ing of a dilated left ventricle with impaired ventricular
systolic function. Left ventricular ejection fraction (LVEF)
and left ventricular diastolic diameter (LVDD) were used
as clinical parameters of the ventricular function for
Chagas disease patients, where LVEF <55 % and LVDD/
body surface area ≥31 mm were used to define Chagas
disease dilated cardiomyopathy [3]. None of the patients
had undergone chemotherapeutic treatment, nor been
previously treated for T. cruzi infection. Healthy individ-
uals with age ranging from 29 to 55 years [mean of 42.6 ±
8.8), from a non-endemic area for Chagas disease with
negative serological tests for the infection were included
in the control group (non-infected NI).
Ethics statement
This study was carried out in full accordance with all
international and Brazilian accepted guidelines and was
approved by the Ethics Committee of the René Rachou
Research Center – FIOCRUZ (14/2006 CEPSH-IRR) and
UFMG protocol COEP-ETHIC 001/79). All enrolled
patients gave written informed consent prior to the inclu-
sion in the study.
Trypanosoma cruzi soluble antigen preparations
The CL strain of T. cruzi was used for antigenic preparation
as described elsewhere [21]. After preparation, the protein
concentration was determined, aliquoted and stored at -
70 °C prior use.
Short-term in vitro whole blood cultures with T. cruzi
antigens
Whole blood samples (final concentration of 1 × 106
cells/mL) were treated with staurosporine (Sigma, St.
Louis, MO, USA) (4 μM), soluble T. cruzi antigens (TcAg)
(25 μg/mL) or untreated (stimulated with medium
alone – RPMI 1640 supplemented with 1.6 % L-glutam-
ine, 3 % antibiotic-antimycotic, 5 % of AB Rh-positive
heat-inactivated normal human serum), and incubated
for approximately 24 h at 37 °C in 5 % CO2. Following
incubation, the cultures were treated with 220 μL of EDTA
at 20 mM and maintained at room temperature for 15 min
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prior immunophenotypic staining for apoptosis assay, cell
surface markers, and intracellular cytokine analysis.
Cell preparation and proliferation assay
PBMC from Chagas patients and healthy individuals were
isolated by Ficolldiatriazoate density gradient centrifuga-
tion (LSM; Organon Teknica, Charlesnton, S.C.) as previ-
ously described (Gomes, 2003). The cells were washed in
RPMI 1640 medium and cultured in flat-bottom 96-well
plates (Nunc Brand Products). Proliferative responses
were evaluated by incubating 2.5 ×105cells/well for TcAg
(25 μg/mL) or 1.5 ×105cell/well for mitogen stimulation
(PHA, 10 μg/mL), respectively, in a final volume of
200 μL of complete RPMI-1640. Incubation was carried
out in a humidified 5 % CO2 incubator at 37 °C for
3 days for PHA-stimulated cultures and 6 days for
antigen-stimulated cultures. Cells were pulsed for the
last 6 h of incubation with 1 μCi of [3H] methyl thymidine
(PerkinElmer LAS, Shelton, CT, USA), and harvested onto
glass fiber filters (Printed Filtermat A, Wallac, Finland).
Radioactive incorporation was determined by liquid
scintillation spectrometry (MicroBeta JET, PerkinElmer
Inc., USA).
Analysis of apoptosis profile
Short-term in vitro whole blood cultures were washed
with 6 mL of FACS buffer (PBS supplemented with 0.5 %
bovine serum albumin-BSA and 0.1 % sodium azide) by
centrifugation at 600xg for 7 min at room temperature
and resuspended in 5 mL of FACS buffer.
For the annexin V analysis, aliquots of 150 μL were
transferred to polystyrene tubes and incubated for 30 min
at room temperature (RT) with 2 μL of allophycocyanin
(APC) – labeled anti-CD4 (RPA-T4) (BD Pharmingen) or
anti-CD8 (RPA-T8) (BD Pharmingen) monoclonal anti-
bodies. Following incubation, the red blood cells were
lysed by the addition of 3 mL of FACS lysing solution
(Becton Dickinson, CA, USA) for 10 min, and cells
washed with 2 mL of PBS by centrifugation at 600 xg for
7 min at room temperature. The cells were resuspended
in annexin V binding buffer (0.1 M Hepes/NaOH (pH 7.4)
1.4 M NaCl, 25 mM CaCl2 - Biosciences, San Jose, CA),
for working solution (1X), then incubated for 15 min at
RT (25 °C) in the dark with 5 μL annexin V-PE and 5 μL
7AAD. The reaction was stopped by the addition of
100 μL of 1x binding buffer for each tube.
For caspase-3 analysis, aliquots of 150 μL of whole
blood cultures were transferred to polystyrene tubes and
incubated for 30 min at room temperature with 2 μL of
fluorescein isothiocyanate (FITC)-labeled anti-CD45 (2D1)
(BD Biosciences) and 2 μL of peridinin chlorophyll-a pro-
tein (PerCP)-labeled anti-CD14 (M5E2) (BD Biosciences)
monoclonal antibodies. The tubes were incubated in the
dark for 10 min at RT. The cells were permeabilized in
saponin buffer (0.5 %) (Sigma) for 15 min at RT in the dark.
Finally, the cells were incubated with PE-conjugated rabbit
anti-active caspase-3 mAb (C92-605) (BD Pharmingem)
using 20 μL/1×106 cells for 60 min at RT in the dark.
Phenotypic analyses were performed by flow cytometry
using a Becton Dickinson FACScalibur flow cytometer
Analysis was performed on 7 × 104 lymphocytes (gated
according to their forward and side scatter properties. The
sample acquisition and data analysis were performed using
CellQuest software (BD Biosciences, USA).
Analysis of cell surface markers and intracytoplasmic
cytokines
Cultured cells were washed twice in PBS containing 1 %
BSA and stained with monoclonal antibodies specific for
cell-surface markers. Antibodies to CD4 (RPA-T4), CD8
(RPA-T8) and CD62L (DREG-56) (all from BD Pharmin-
gen) were used. The cells were then fixed in formalde-
hyde (4 %) and permeabilized in saponin buffer (0.5 %)
(Sigma, USA) for 15 min. Finally, the cells were incu-
bated with anti-TNF-α (PE) (L293) (BD Biosciences)
washed and ressuspended in FACS buffer prior acquisi-
tion in flow cytometer.
Phenotypic analyses were performed by flow cytometry
using a Becton Dickinson FACScalibur flow cytometer,
collecting data on 7 × 104 lymphocytes gated according
to their forward and side scatter properties. The sample
acquisition and data analysis were performed using Cell-
Quest software (BD Biosciences, USA).
Detection of plasmatic cytokine levels by Cytometric
Bead Array (CBA)
A cytometric beads array (CBA) immunoassay kit (BD
Biosciences, USA) was used to measure cytokine levels
(IFN-γ, TNF-α, IL-2 and IL-10) in plasma as described
in previous studies [6]. The data were acquired in a
Becton Dickinson FACScalibur flow cytometer and ana-
lyzed using BD CBA software (BD Biosciences, USA).
The results were expressed by mean intensity of fluor-
escence (MIF).
Apoptotic pathways triggered by T. cruzi infection in
different clinical forms of Chagas disease
In order to determine putative apoptotic pathways trig-
gered by T. cruzi infection, PBMC from infected patients
IND (n = 2) and CARD (n = 2) were incubated only with
culture medium- culture non-stimulated; or in the pres-
ence of antigen- culture stimulated with TcAg at a final
concentration of 25 μg/mL. After 18 h of incubation at
37 °C and 5 % CO2 air, cells were recovered and washed
with PBS. Subsequently, cells were submitted to a total
RNA extraction protocol using NucleoSpin® RNA II kit
(Macherey-Nagel, Germany). The total RNA was quantified
according to standard procedures using spectrophotometer
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(Thermo Scientific, USA) and evaluated in agarose gel to
confirm its integrity [22]. The cDNAs were obtained with
Superscript II kit (Invitrogen, USA) using 120 ng of total
RNA, according to manufacturer’s instructions. Afterwards,
a RT-PCR reaction was performed using previously estab-
lished constitutive human primers to confirm the cDNA
synthesis.
The apoptotic transcripts were evaluated using a Human
Apoptosis RT2 Profiler™ PCR Array kit (SABiosciences,
USA) in a qPCR machine (7500, Applied Biosystem, USA),
according to manufacturer’s instructions. Thirty one tran-
scripts involved with pro-apoptotic activity were evaluated.
Out of thirty one genes, twenty belong to TNF and TNF re-
ceptor superfamily, cell death domains and inductors of
apoptosis; and eleven to the caspases family, which are also
involved with pro-apoptotic activity. The qPCR data were
analyzed by PCR Array Data Analysis Web Portal (SABios-
ciences, USA), and the results were expressed using the
method of 2-ΔΔC.
Statistical analyses
Statistical analyses were conducted using the R 2.15.0
software. Initially, the Anderson-Darling test was applied
to verify whether the obtained data represent a normal
distribution. Statistical comparative analyses were per-
formed using the non-parametric: Mann–Whitney test
to compare two groups (NI x IND or NI x CARD or IND x
CARD); Kruskal-Wallis test to compare three groups (NI x
IND x CARD) and, together with the Bonferroni correction
(significance level, 0.05/3 = 0.0167). All tests were per-
formed considering a significance level of 5 % (α = 0.05).
Results
Cellular proliferative response is decreased in CARD
patients
The proliferative immune response was analyzed in
PBMC from IND and CARD patients as well as NI indi-
viduals stimulated with soluble T. cruzi antigens (TcAg)
by the quantification of H3-thymidine incorporation. We
observed that PBMC proliferative response of the IND
group had a significantly higher (p < 0.05) level of cellu-
lar proliferation after stimulation with TcAg when com-
pared with CARD and NI groups (Fig. 1). No significant
difference was observed in the proliferative response in-
duced by PHA (data not shown).
Increased downregulation of CD62L in CD4+ T cells is
related to CARD patients
We also evaluated the loss of expression (CD62L−) in
circulating CD4+ and CD8+ T cells, before and after in
vitro stimulation with TcAg. The analysis showed signifi-
cant increase on the percentage of CD4+CD62L− cells in
CARD patients (p < 0.05) in ex vivo analysis as well as
non-stimulated cultures when compared with NI and IND
groups (Fig. 2a). Moreover, after TcAg in vitro stimulation,
a higher percentage of CD4+CD62L− cells in CARD pa-
tients (p < 0.05) it was also observed when compared to
NI individuals (Fig. 2a). Ex vivo expression of CD62L− by
CD8+ cells and after in vitro culture in the presence or
not of TcAg did not show any statistically significant dif-
ferences between the study groups (Fig. 2b).
Lymphocytes from IND and CARD patient presented
elevated frequency of apoptosis after in vitro TcAg
stimulation
The low proliferative response and high percentage of
CD4+CD62L− T cells observed in CARD patients might
be related to regulatory mechanisms involved in the
control of the immune response induced by T. cruzi. In
this context, apoptosis has been previously demonstrated
as play a role in experimental model of acute T. cruzi in-
fection [23–26] and also in human heart tissues [27]. In
order to investigate if apoptosis might be a factor related
to the lower proliferative response and if it is caused by
high T cell activation in the CARD patients, the frequency
of annexin V+ and active caspase 3+ was analyzed as
markers of apoptosis.
Our data show that after in vitro stimulation with
TcAg the lymphocytes from CARD displayed high fre-
quency of annexin V+ when compared with IND and NI
groups (Fig. 3a). The higher frequency of annexin V+ in
CD4+ T cells was observed in IND and CARD patients
as compared to NI (Fig. 3b). On the other hand, lower
frequency of annexin+ in CD8+ T cells were observed in
Fig. 1 Proliferation of peripheral blood mononuclear cell induced by
T. cruzi antigens (TcAg). A total of 3×105 cells/well isolated from
non-infected (NI) (n = 15), indeterminated (IND) (n = 15) and cardiac
(CARD) (n = 15) groups were cultured in the presence of medium
(RPMI-10 % AB serum) and TcAg (25 μg/mL) for 5 days, the last 18 h
in the presence of 0.5 μCi[3H]-thymidine. The thymidine incorporation
was measured by liquid scintillation spectroscopy. Data were reported as
means of triplicates of counts per minute (cpm). Significant differences
(p-value < 0.05) in the charts are identified by connecting lines and the
symbol (*) for comparisons between the groups. Mann–Whitney test
was used for comparison and the results were expressed as the median
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IND and NI groups as compared with CARD group
(Fig. 3c). A similar profile was observed for the cultures
in the presence of Staurosporin-STP, a positive control
for apoptosis.
The frequency of total lymphocytes and CD4+ or
CD8+ T cells subsets from IND and CARD patients exhib-
ited similar apoptosis profile as compared with NI individ-
uals when active caspase 3+ was analyzed (Fig. 3a and b,
respectively).
Activated Lymphocytes+ TNF-α+ form CARD patients were
susceptible to apoptosis
A second hypothesis to explain the induction of pro-
grammed cell death in lymphocytes from chagasic patients
involves the cytokine environment. It is known that TNF-
α is a major cytokine implicated in the apoptosis pathway.
Thus, we have further evaluated serum levels and intracy-
toplasmic expression of this cytokine ex vivo and following
incubation with TcAg. We observed that plasma from
Fig. 2 Analysis of percentage of downregulation of CD62L by CD4+ (a) and CD8+ (b) T cell subsets in the peripheral blood from chagasic patients, in ex
vivo context and after in vitro stimulation with T. cruzi antigens, from patients with distinct clinical forms of Chagas disease: indeterminate – IND (n= 9, gray
bars); cardiac – CARD (n = 14, black bars) and non-infected individuals – NI (n = 15, white bars). The results were expressed as mean ± standard
deviation (SD). Significant differences (p < 0.05) in the charts are identified by connecting lines for comparisons between groups
Fig. 3 The apoptotic profile of T lymphocytes from peripheral blood of uninfected individuals (NI) and patients with Chagas disease - indeterminate
(IND) or cardiac (CARD) form. The detection of apoptosis was performed using the percentage of annexin+ (panel a) and caspase 3+ (panel b) in total
lymphocytes, CD4+ or CD8+ T cell subsets. The lymphocytes were evaluated without stimulation - control cultures (C) and after in vitro stimulation
with TcAg (T. cruzi antigens) and STP (staurosporin). Mann–Whitney test was used for comparison and the results were expressed as the median with
interquartile range. Differences (p < 0.05) are presented by the corresponding numbers and connecting lines in the box plot graphs
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CARD patients presented a higher expression of TNF-α
than IND and NI groups (p < 0.05). Also, after TcAg
stimulation, chagasic patients (IND and CARD) presented
a higher frequency of TNF-α by total lymphocytes
(Fig. 4b), and CD4+ T or CD8+ T cells when compared
with NI groups (Fig. 4c and d, respectively). Analysis of
serum levels of IFN-γ and IL-10 were also performed.
IFN-γ was elevated in sera from cardiac patients and
IL-10 in indeterminate patients as previously shown
[28]. In this study we observed that IL-2 was also elevated
in sera from cardiac patients (Additional file 1). These re-
sults did not show any association with apoptosis.
To determine whether TNF-α expression by total lym-
phocytes and CD4+ or CD8+ T cells subsets is associated
with the frequency of apoptosis, we performed a correla-
tive analysis between the frequency of apoptosis and
TNF-α expression. We observed a positive and signifi-
cant correlation between high frequency of annexin+ in
CD4+ T cells and high frequency of TNF-α in CD4+T
cells both in IND and CARD groups. Moreover, a signifi-
cant positive correlation was found, between frequency
of annexin+CD8+ T cells and TNF-α+CD8+T cells in
CARD group (Fig. 4d). Together, these results suggested
that both CD4+ and CD8+ T cells from CARD patients















































Fig. 4 Analyses of cytokine levels and their association with cardiac morbidity expressed by the clinical classification. (a) The analysis of plasma
cytokine levels was performed as described in material and methods. The groups evaluated were: NI (n = 15, white box), IND (n = 15, light gray
box), and CARD (n = 15, dark gray box). The results were expressed by mean intensity of fluorescence (MIF). Plasma TNF-α levels in NI, IND, and
CARD groups and their association with cardiac morbidity. (b, c) Analysis of percentage of CD4+TNFα+ and CD4+TNFα+ T cells in the peripheral
blood from chagasic patients, in ex vivo context and after in vitro stimulation with T. cruzi antigens, from patients with distinct clinical forms of
Chagas disease. Significant differences (P-value < 0.05) in the charts are identified by connecting lines and the symbol (*) for comparisons between the
groups. (d) Correlation analysis between percentage of annexin+ CD4+ and annexin+ CD8+ T cells and TNF-α intracytoplasmic in the IND (n = 15) and
CARD (n = 15) groups. Mann–Whitney test was used for comparison and the results were expressed as the median. Correlation analysis were done
using the Spearman correlation coefficient, and the results were considered significant with a p-value < 0.05. Significant differences (P-value)
are indicated in each graph together with the r values
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expressing TNF-α were highly susceptible to undergo
apoptosis upon in vitro stimulation.
Cell apoptosis in CARD patients might be induced by TNF
receptors superfamily and/or caspase family pathway
Once we showed that CARD patients presented higher
frequency of apoptotic cells, the next step was to identify
the possible apoptotic pathway used to activate T apop-
tosis in T cells from patients with this clinical form, before
and after in vitro stimulation with TcAg antigen. Initially,
31 apoptosis-related genes from TNF/TNFR superfamily
and Caspase family were grouped and categorized accord-
ing to their respective families and function. Analysis of
the others 53 genes of human apoptosis pathway were also
performed and these results did not show any significant
differences in all groups (data not shown).
In the absence of in vitro TcAg stimulation, when we
evaluated the TNF/TNFR superfamily genes from CARD
group was determined. The results showed that cell death
receptors (FADD, TRADD, TNFRSF10A (TNF receptor
superfamily member 10A), TNFRSF10B, TNFRSF11B,
TNFRSF21 and TNFRSF25) were up-regulated when com-
pared with IND group (Fig. 5a). Moreover, other pro-
apoptotic genes (FAS, FASL, TNFSF8, TNFRSF9, TRAIL,
TRAF2) were also up-regulated in CARD patients when
compared with individuals from the IND group (Fig. 5a).
When also evaluated the caspase family genes, the results
showed that caspase 1 (CASP1), caspase 2 (CASP2),
caspase 3 (CASP3), caspase 4 (CASP4), caspase 5 (CASP5),
caspase 7 (CASP7), caspase 9 (CASP9), caspase 10
(CASP10) and caspase 14 (CASP14) genes, were up-
regulated in CARD group in comparison with IND
patients (Fig. 5b).
Interestingly, the in vitro TcAg stimulation increased
considerably the expression of cell death TNF/TNFR
superfamily as well as caspase family receptors genes
(FADD, TRADD, TNFRSF10A, TNFRSF10B, TNFRSF11B,
TNFRSF21, TNFRSF25, TNFSF10, FAS, FASLG, TNFRSF9,
TNFSF8, TRAF2, TRAF4) (Fig. 5c and d, respectively). Fur-
thermore, high expression of genes such as TNFRSF1A,
CD27, LTA, TRF3, TRF4 and CASP3 were observed after
PBMCs cultures from CARD when compared to IND pa-
tients (Fig. 5c and d, respectively). Moreover, the CD70
gene was downregulated in CARD patients when compared
to IND patients (Fig. 5c).
Discussion
In the present work, we have shown that apoptosis is
associated with reduced proliferative response, a high
expression of T CD4+CD62L− cells, an increase TNF-α
intracellular production and expression of genes of cell
death TNF/TNFR superfamily and caspase family in
CARD patients.
In this context, some studies have been shown that
CARD patients presented low proliferation of T cells
when compared with healthy and non-chagasic cardio-
myopathy donors [29–32]. Although, the mechanisms of
proliferative dysfunction in Chagas disease need further
investigation, studies suggest that they could be related
to the decrease of co-stimulatory molecules expression,
receptor cytokine starvation or expression of inhibitory
receptors as PD-1 [12, 32, 33].
Some studies suggest that activated cells are suscep-
tible to apoptosis, which may represent a mechanism of
immunoregulation [34, 35]. To assess the activation sta-
tus of T cell subsets, we evaluated whether CD62L is
downregulated in these cell subpopulations. Our data
showed that CARD patients presented a significantly
higher percentage of TCD4+CD62L− cells suggesting
that a putative involvement of this cell type in the ex-
acerbation of the immune response to the parasite and,
consequently, on the development of myocarditis by cell
death induced by activation. Dos Santos et al. [36] showed
that the majority of TCD4 and TCD8 lymphocytes in the
inflammatory foci from the heart of chagasic patients did
not express or slightly expressed CD62L and T CD8+ cells
are the majority of the activated cells in the tissue when
compared with CD4+ T cells. The inflammatory process
occurring in Chagas’ disease mainly consists of CD8 T
lymphocytes, CD4 T lymphocytes and macrophages. The
extent of inflammatory reaction and the tissue damage
caused may contribute to loss of myocardial cells, and to
the heart failure that is observed on more severe cases of
chronic Chagas’ disease. Tostes Jr et al. [37] showed that
myocardial cell loss by apoptosis and fibrosis contributes
to heart failure in the chronic phase of Chagas’ disease. In
fact, apoptosis has been considered a cause of heart failure
in other diseases such as myocardial infarction and heart
hypertrophy [38, 39], as well as a mechanism involved in
the control of the immune response in experimental
models [26]. On the other hand, heart failure by itself may
induce apoptosis [40].
In this work, high expression of annexin by lympho-
cytes from CARD group was observed when compared
with IND and NI groups, as well as an increase on the
expression of annexin by CD4+ T cells and caspase by
both CD4+ and CD8+ T cells by chagasic patients when
compared with NI group after in vitro stimulation with
T. cruzi antigens. In Chagas’ disease, the occurrence of
apoptosis in T lymphocytes was observed after antigen
stimulation in experimental models [26] although its
significance in terms of clinical form or outcome of the
disease was not clear. Apoptosis-like death has been re-
ported in amastigote nests and trypomastigotes forms
from T. cruzi, and this mechanism has been associated
with control of parasite burden regulated by the parasite
itself or by the host, parasite evasion of the host’s immune
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response and clonal selection [41–44]. Together, these
findings suggest that although the lymphocytes from
CARD patients presented lower proliferative response
upon antigenic recall, lymphocytes from IND and CARD
patients presented a singular ability to undergo apoptosis
that may reflect different regulatory mechanism.
Rodrigues et al. [45] demonstrated a high percentage
of lymphocyte apoptosis in patients with a severe cardiomy-
opathy, associating this event to activation of programmed
death pathways, by Fas/Fas-L or TNF-α receptors, leading
to parasite escape, and consequently, to a continuous
stimulation of the immune system. In this context, T cells
apoptosis in experimental model leads to an increase of
parasite growth [46]. Indeed, apoptosis has been suggested
to be an important mechanism to control the immune re-
sponse and heart damages [47].
In order to determine whether TNF-α contributes to
T cell apoptosis, the plasmatic and intracellular production
by Tcell subsets was evaluated. Our data demonstrated that
CARD group showed increased levels of circulating and
intracytoplasmic TNF-α, and up-regulation of the TNF re-
ceptor gene superfamily. Lula et al. [48] have shown correl-
ation among soluble ligands of TNF superfamily (TNF-α,
TRAIL and FasL/CD95L) and functional disorders of the
left ventricle in chronic chagasic patients with cardiomyop-
athy. These results are associated with ligand receptors
associated with programmed cell death, suggesting that
apoptotic mechanisms are involved with the development
of miocardiopathy in Chagas disease.
Ferreira et al. [49] showed a correlation between high
serum levels of TNF-α and the occurrence of severe
Chagas cardiomyopathy. Also, it has been shown that
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Fig. 5 Apoptotic pathways presented by PBMCs from T. cruzi-infected patients, displaying different clinical forms of the Chagas disease. Relative
analysis of genes expression from TNF/TNFR superfamily members, and Caspase family members were evaluated. The fold-change values (2-ΔΔCt)
were represented by the bars, which show the expression of apoptotic genes from T. cruzi-infected patients presenting the cardiac clinical form
(CARD) in comparison to T. cruzi-infected patients presenting the indeterminate clinical form (IND). a and b- Culture non-stimulated; c and
d- Culture stimulated with TcAg
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there is an inverted correlation between high levels of
TNF-α with the lowest left ventricular ejection fraction
seen in patients with chronic Chagas cardiomyopathy
[50]. Moreover, patients with heart failure are shown to
have a significantly lower PBMC proliferative response
but higher levels of apoptosis and Fas and Fas-L expres-
sion [45]. TNF-α may play a role on the high levels apop-
tosis and in the low proliferative response observed in
patients with heart failure. TNF-α may contribute to the
induction of apoptosis by the interaction with its receptor
or by induction of Fas and Fas-L expression [51]. Our re-
sults suggest that the high levels of TNF-α detected in
plasma from CARD group may contribute to the heart
condition. Additionally, our data support the hypothesis
that high levels of TNF-α and up-regulation of the TNF
receptor gene superfamily lead to an increase in apoptosis,
and consequently the exacerbation of the pathology.
Conclusions
Here, we showed that apoptosis is associated with low
proliferative response, intense T cell activation, high
TNF-α production and up-regulation of genes associated
with TNF receptors superfamily and caspase family in
CARD ’patients. These results suggest that apoptosis
could interfere on the development and/or maintenance
of the different clinical forms of Chagas disease. Assum-
ing that the immunological regulation in the IND group,
may control the development of Chagas cardiomyop-
athy, the absence of this mechanism in the CARD group,
may be one of the factors associated with sustained in-
flammation which would, consequently, lead to a higher
morbidity in the latter group. The association of
lymphocyte apoptosis, induced by the constant activa-
tion of the immunological system, with high levels of in-
flammatory cytokines and associated pathological events
(fibrosis and apoptosis) may contribute with the devel-
opment and progression of heart injuries in the chronic
phase of the human Chagas disease.
Additional file
Additional file 1: Figure S1. Analyses of plasma cytokine levels
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Plasma IL-2 levels in NI, IND, and CARD groups. (C) Plasma IFN-γ levels in NI,
IND, and CARD groups. (D) Plasma IL-10 levels in NI, IND, and CARD groups.
Significant differences (P-value < 0.05). Statistical comparative analyses were
performed, in groups of two, between the NI, IND, and CARD groups, using
the non-parametric Kruskal-Wallis test and Mann–Whitney U test, together
with the Bonferroni correction (significance level, 0.05/3 = 0.0167). The letters
represent statistically significant differences (p < 0.05) between the
groups: a = difference when compared to NI group; b = difference when
compared to IND group; c = difference when compared to CARD group.
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